Loading company…
VAXIMM develops oral T-cell immunotherapies for cancer.
Founded in 2008 and based in Basel, Switzerland, VAXIMM develops oral T-cell immunotherapies designed to activate immune responses against tumor-specific neoantigens. Its therapies target cancers including solid tumors. In March 2022, NEC Oncoimmunity AS acquired VAXIMM's Neoantigen Vaccine Development Assets; investors in the company included BB Biotech and Merck Generics.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in